Statin Drug Interactions
Statin interactions primarily involve CYP3A4 and OATP1B1 transporter inhibition, raising statin plasma levels and the risk of myopathy and rhabdomyolysis.
## Why Statin Interactions Are Dangerous
Statin myopathy and rhabdomyolysis are concentration-dependent adverse effects. Drug interactions that increase statin plasma levels elevate these risks substantially. The cerivastatin-gemfibrozil combination caused over 50 rhabdomyolysis deaths before cerivastatin was withdrawn in 2001.
## Metabolic Pathways
Different statins use different metabolic routes, creating distinct interaction profiles:
| Statin | Primary CYP | OATP1B1 | Interaction Risk |
|--------|------------|---------|-----------------|
| Simvastatin | CYP3A4 | Yes | Highest |
| Lovastatin | CYP3A4 | Yes | High |
| Atorvastatin | CYP3A4 | Yes | Moderate |
| Rosuvastatin | CYP2C9 (minor) | Yes | Lower |
| Pravastatin | Non-CYP | Yes | Lowest |
| Pitavastatin | Minimal CYP | Yes | Low |
## CYP3A4-Mediated Interactions
Simvastatin and lovastatin are the most vulnerable. Strong CYP3A4 inhibitors can increase their AUC by 10-20 fold:
- **Contraindicated**: itraconazole, ketoconazole, posaconazole, HIV protease inhibitors (except with dose-limited atorvastatin), clarithromycin
- **Dose limits**: simvastatin max 20 mg with amiodarone, amlodipine, or diltiazem; max 10 mg with lomitapide
- **Moderate inhibitors**: erythromycin, verapamil, fluconazole — require dose reduction
Atorvastatin is less sensitive but not immune. Combining atorvastatin with itraconazole increases its AUC 3-fold.
## OATP1B1 Transporter Interactions
OATP1B1 mediates hepatic uptake of all statins. Inhibitors cause systemic statin accumulation:
- **Cyclosporine** — the most potent OATP1B1 inhibitor; increases rosuvastatin AUC 7-fold, pravastatin 5-fold. Most statins are contraindicated or severely dose-limited with cyclosporine.
- **Gemfibrozil** — inhibits OATP1B1 and glucuronidation; increases simvastatin acid AUC 2-3 fold. Combination with any statin increases myopathy risk. FDA recommends avoiding gemfibrozil-statin combinations; fenofibrate is preferred.
## Other Interactions
- **Colchicine** — independent myotoxicity; combined with statins increases myopathy risk, especially in renal impairment
- **Daptomycin** — causes myopathy independently; consider temporarily holding statins during daptomycin courses
- **Niacin** — modest additive myopathy risk at doses above 1 g/day
- **Grapefruit juice** — inhibits intestinal CYP3A4; clinically relevant for simvastatin and lovastatin with large quantities (>1 quart/day)
## Safe Prescribing
1. **Prefer low-interaction statins** (rosuvastatin, pravastatin, pitavastatin) in patients on complex regimens
2. **Check FDA-recommended dose limits** for each statin-inhibitor pair before prescribing
3. **Counsel patients** to report unexplained muscle pain, tenderness, or dark urine immediately
4. **Check CK** only if symptomatic; routine CK monitoring is not recommended
5. **Use fenofibrate** instead of gemfibrozil when fibrate-statin combination is needed
## Key Takeaways
- Simvastatin and lovastatin have the highest interaction risk due to CYP3A4 dependence
- Cyclosporine inhibits OATP1B1, dramatically increasing all statin levels
- Gemfibrozil-statin combinations increase myopathy risk; use fenofibrate instead
- Rosuvastatin, pravastatin, and pitavastatin have the lowest CYP-mediated interaction risk
- FDA dose limits exist for many statin-inhibitor pairs; consult product labeling